Clinical trial
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT00347425
Study timeline
Study start (unknown)2006-12-01Date precision: month
Registry last updated2008-05-21
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
AripiprazoleDRUG · verified · RxNorm: aripiprazole
OlanzapineDRUG · verified · RxNorm: olanzapine
RisperidoneDRUG · verified · RxNorm: risperidone
QuetiapineDRUG · verified · RxNorm: quetiapine
ZiprasidoneDRUG · verified · RxNorm: ziprasidone
AripiprazoleDRUG · verified · RxNorm: aripiprazole
OlanzapineDRUG · verified · RxNorm: olanzapine
RisperidoneDRUG · verified · RxNorm: risperidone
QuetiapineDRUG · verified · RxNorm: quetiapine
ZiprasidoneDRUG · verified · RxNorm: ziprasidone
Sponsors & collaborators
Solvay Pharmaceuticalslead sponsor
H. Lundbeck A/Scollaborator
Wyeth is now a wholly owned subsidiary of Pfizercollaborator
Mapped research locations
BudapestHungary4PhiladelphiaPennsylvania, United States2St LouisMissouri, United States2San DiegoCalifornia, United States2PragueCzechia2MemphisTennessee, United States2Buenos AiresArgentina2New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00347425 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.